Accueil>>Apraglutide

Apraglutide (Synonyms: FE 203799)

Catalog No.GC34473

L'apraglutide (FE 203799), un peptide synthétique de 33 acides aminés et un analogue du GLP-2 À action prolongée, améliore l'adaptation et la croissance intestinale linéaire dans un modèle de porcelet néonatal du syndrome de l'intestin court avec résection totale de l'iléon .

Products are for research use only. Not for human use. We do not sell to patients.

Apraglutide Chemical Structure

Cas No.: 1295353-98-8

Taille Prix Stock Qté
1mg
108,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum[1].

Apraglutide (FE 203799; 5 mg/kg/dose, subcutaneously, twice on days 0 and 4 postsurgery) treated piglets are healthy, have significant lower fecal fat and energy losses and exhibite intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth on day 7[1]. Animal Model: NewbornDuroc piglets, 2-5 days old and weighing between 2-2.6 kg[1].

[1]. Slim GM, et al. Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. JPEN J Parenter Enteral Nutr. 2019 Jan 6.

Avis

Review for Apraglutide

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Apraglutide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.